期刊
FRONTIERS IN BIOSCIENCE-LANDMARK
卷 11, 期 -, 页码 788-803出版社
FRONTIERS IN BIOSCIENCE INC
DOI: 10.2741/1837
关键词
vaccinia; fowlpox; immunotherapy; treatment; therapeutics; costimulation; TRICOM; B7-1; ICAM-1; LFA-3; review
资金
- NATIONAL CANCER INSTITUTE [Z01BC010662, Z01BC010661, ZIABC010661] Funding Source: NIH RePORTER
Tumor-associated antigens (TAAs) are by definition either weakly immunogenic or functionally nonimmunogenic. Therefore, efforts have concentrated on the development of vaccine strategies in which the presentation of TAAs to the immune system results in far greater activation of T cells than that occurring naturally in the host. Several strategies are being explored in our laboratory and others to enhance the immunogenicity of TAAs. These are: ( a) placing the gene coding for the tumor antigen, as a transgene, into poxvirus vectors. (b) The use of diversified prime and boost vaccine strategies employing two different types of poxvirus vectors. (c) The use of T-cell costimulation; accomplished by placing transgenes for different T-cell costimulation molecules into viral vectors along with the transgenes for the TAA. (d) Altering the amino acid sequence of the TAA to enhance the host immune response. (e) The use of cytokines, and in particular GM-CSF, as a biologic adjuvant. This review will focus on the current state of the use of costimulatory molecules as adjuvants for immunotherapy, and in particular, as immunomodulators for cancer vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据